ClinicalTrials.gov
ClinicalTrials.gov Menu

Practicing Self-Control Lowers the Risk of Smoking Lapse

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00349687
Recruitment Status : Completed
First Posted : July 10, 2006
Last Update Posted : November 23, 2011
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Mark Muraven, University at Albany

Study Description
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The proposed study will investigate the role of self-control in smoking cessation and whether interventions that improve self-control can help reduce the risk of lapsing among smokers who wish to quit. Our model predicts that the regular practice of self-control should lead to a building of strength and a general improvement in self-control performance. Hence, smokers who practice self-control prior to quitting should be more likely to succeed in their cessation attempt than smokers who do not practice self-control

Condition or disease Intervention/treatment Phase
Behavior, Addictive Cigarette Smoking Behavioral: self-control practice Phase 1 Phase 2

Study Design
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Practicing Self-Control Lowers the Risk of Smoking Lapse
Study Start Date : May 2004
Actual Primary Completion Date : March 2009
Actual Study Completion Date : March 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Smoking
U.S. FDA Resources

Arms and Interventions
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. smoking cesssation [ Time Frame: 1 month ]

Eligibility Criteria
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • smoked at least 10 cigarettes per day for at least two years
  • currently smoking

Exclusion Criteria:

  • have at least an 8th grade education level
  • have a working touch-tone phone
  • report low motivation and efficacy to quit
Contacts and Locations
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00349687


Locations
United States, New York
University at Albany
Albany, New York, United States, 12222
Sponsors and Collaborators
University at Albany
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Mark Muraven, Ph.D. University at Albany
More Information
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Mark Muraven, Associate Professor, University at Albany
ClinicalTrials.gov Identifier: NCT00349687     History of Changes
Other Study ID Numbers: DA016131
R01DA016131 ( U.S. NIH Grant/Contract )
First Posted: July 10, 2006    Key Record Dates
Last Update Posted: November 23, 2011
Last Verified: November 2011

Additional relevant MeSH terms:
Behavior, Addictive
Compulsive Behavior
Impulsive Behavior